Research
Hormonal
The transcription factor PRDM16 controls the bidirectional switch between skeletal muscle and brown adipose tissue, promoting brown adipogenesis.
PRDM16 is a key regulator of brown fat development in rodents. While it offers a promising molecular target for future obesity treatments, its direct application in humans is not yet established.
ModerateSupportsMEDIUM confidence
a new transcription factor called PDRM16 may control a bidirectional switch between skeletal muscle and BAT
Why this rating
Based on rodent genetic studies cited in a review paper; human applicability is noted as unknown.
Source
Have we entered the brown adipose tissue renaissance?
Éric Ravussin et al. · Obesity Reviews · 2009
DOI 10.1111/j.1467-789x.2008.00559.x
narrative_reviewCited 63×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →